Greatland Resources has released its FY2025 unaudited results, delivering $961m revenue, $601m operating cash flow and closing cash of $575m. Strong progress at Telfer & Havieron sets a solid foundation for FY2026. Full report: bit.ly/47NRlds $GGP.L #GPP #Greatland

You’re reminded any solution to #AVCT’s CLN was previously dismissed as unobtainable because obstructive noteholders made it impossible. Turns out if you stick a proven deal-maker around the table you will find a solution. #Hughes4Chair

If you are confident of near term catalysts to send the SP significantly north…. Defer bond payments to aid cash flow and reduce dilution upon payback to protect share holders. Finally we have financially astute people leading #avct forward alongside the incredible science. 🌟

Today’s deferment of the loan note protects shareholders and restores value; allowing #AVCT to focus on the advancement of preCISION. TVR5 would like to see Richard Hughes move into an executive position. His track record of protecting shareholders is clear. #Hughes4Chair

#AVCT board admitted they couldn’t fix the toxic debt (CLN) after 3 yrs. New NED Richard Hughes has succeeded where others failed. Cracking it in months. Pre|CISION just did the same in clinic with FAP. #Hughes4Chair - It works.

Absolutely HUGE news for Avacta #AVCT. Key points: 1) The market now need not worry about the next three repayment installments to Heights. The company has now at least ten months before any further shares are issued to Heights. After October's payment (which will be settled

Absolutely bloody marvellous linkedin.com/posts/andy-hol…

#AVCT need cash yet have turned it down. Heights have agreed to defer our next 2 CLN payments even though the revenue generating diagnostics business has gone. RH & Zeus have paid October's CLN off early ESMO is coming in October and Dr Tap is presenting our latest data for

#AVCT currently valued at ~ $250m Panmure Liberium estimating total peak sales of FAP dox & FAP ext (breast, Ovarian, Pancreatic & Cervical only) to be $2.6Bn Let's be conservative and say this is valued at only a 4x multiple by big pharma and let's assume a further 100m

Avacta announces that all closing conditions to the sale of Coris Bioconcept SRL to 3B BlackBio Dx Ltd have been satisfied and the completion of the sale took place on Friday August 29, 2025. avacta.com/avacta-announc… #AVCT

Strategic Entry Point for Pharma #AVCT is a rare anomaly: a clinically derisked, modular oncology platform trading at £220m ($270m). By comparison, Seagen, Immunomedics, and Moderna only attracted Pharma engagement at multibillion valuations, often without the level of

#AVCT

How about completing last years accounts instead of spending on more projects and turning off replies….

#ROCK Great news and more to come as we know re drilling . We go up even higher today . 💥 lse.co.uk/rns/molaoi-res…

#ORCP another big spike up coming. The placing shares have already been flipped and in sticky hands and that suggest’s 0.03p as the first big target but they have very high quality assets and valuable and have a tiny mkt cap. This was trading at 0.03o just a couple of weeks ago

A representative of TVR5 is booked and delighted to be heading to Berlin for #ESMO25 to hear W.Tap present Avacta’s new data on FAP-Dox (AVA6000). ✈️🇩🇪🧬 #AVCT #PeptidesCreateHope #HopeWithoutCompromise #Hughes4Chair #LetsDoThis

#ORCP gaining attention and rightly so. 👀

#AVCT precision widening the therapeutic index Higher doses, for longer = better outcomes. It was never just about chemo.

#AVCT updated website rolling out with the homepage. Gives a flavor for what our technology can do #HopeWithoutCompromise

#AVCT website updates 'rolling out' - Coris and diagnostics removed from the About page just now avacta.com/about/